fatnews.com Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Follow @fatnews

    Qsymia (phentermine / topiramate) can cause Cognitive Impairment


    Posted by .(JavaScript must be enabled to view this email address)
    Thursday, July 19, 2012 10:59 am Email this article

    Here is information about the possibility of Cognitive Impairment with the use of Qsymia (phentermine / topirimate) as shown in the prescribing information.

    Cognitive Impairment

    Qsymia can cause cognitive dysfunction (e.g., impairment of concentration/attention, difficulty with memory, and speech or language problems, particularly word-finding difficulties).

    Rapid titration or high initial doses of Qsymia may be associated with higher rates of cognitive events such as attention, memory and language/word-finding difficulties [see Adverse Reactions].

    Since Qsymia has the potential to impair cognitive function, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain Qsymia therapy does not affect them adversely.

    If cognitive dysfunction persists consider dose reduction or withdrawal of Qsymia for symptoms that are moderate to severe, bothersome, or those which fail to resolve with dose reduction. 

    Info about Qseymia

    Info about Qseymia from the FDA

    The following information is from the FDA’s press release.

    “The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

    “BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity and overweight categories.

    “According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.

    “Obesity threatens the overall well being of patients and is a major public health concern,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.

    “Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition.”

    “Qsymia is a combination of two FDA-approved drugs, phentermine and topiramate, in an extended-release formulation.

    “Phentermine is indicated for short-term weight loss in overweight or obese adults who are exercising and eating a reduced calorie diet.

    “Topiramate is indicated to treat certain types of seizures in people who have epilepsy and to prevent migraine headaches.”

    Reference

    Qsymia full prescribing information. July 17, 2012.
    http://www.qsymia.com/pdf/full-prescribing-information.pdf

    More Info

    More info about Qsymia here

    Drug companies website:

    Other Articles

    Other articles about Qsymia (formerly Qnexa)

    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.